Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Decrease in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,400 shares, a decline of 76.7% from the January 15th total of 14,600 shares. Based on an average daily volume of 14,800 shares, the days-to-cover ratio is presently 0.2 days.

Bavarian Nordic A/S Trading Up 3.6 %

BVNRY traded up $0.28 during trading on Thursday, reaching $8.16. 4,142 shares of the company were exchanged, compared to its average volume of 9,155. Bavarian Nordic A/S has a 52 week low of $6.86 and a 52 week high of $14.60. The firm has a 50 day moving average of $8.86 and a 200 day moving average of $10.09. The stock has a market cap of $1.93 billion, a P/E ratio of 11.83 and a beta of 1.68.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.